ReportsFY23 revenue $58.7M vs $151.9M last year.”We expect that 2024 will be an important year for MacroGenics, with multiple pipeline advancements anticipated,” said Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics. “Late last year, we completed enrollment of 177 patients in the TAMARACK Phase 2 study of vobra duo, which was ahead of schedule. We plan to present the initial TAMARACK clinical data in the second quarter of this year. Later in the year, we expect to share updated clinical data from the trial. In addition, we continue to enroll the LORIKEET Phase 2 study of lorigerlimab in mCRPC and expect to start enrolling patients in the dose expansion portion of the combination study of vobra duo and lorigerlimab. Finally, we are excited about the potential of our topoisomerase I inhibitor-based ADCs, including MGC026, for which we recently began a Phase 1 study, and MGC028, for which we anticipate submitting an IND by year end.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MGNX:
- MacroGenics Provides Update on Corporate Progress and 2023 Financial Results
- MacroGenics price target raised to $24 from $12 at BTIG
- MacroGenics to Participate in Upcoming Investor Conferences
- MacroGenics price target raised to $23 from $12 at Barclays
- MacroGenics Announces Date of Fourth Quarter 2023 Financial Results Conference Call